Personalized Approach
At the Englander Institute for Precision Medicine (EIPM) at Weill Cornell Medicine (WCM) and NewYork-Presbyterian Hospital (NYP), we are changing the face of how we diagnose, treat, and care for patients using a personalized approach. Our faculty and staff — physicians, scientists, and administrators strive every day to provide the best patient care and to discover innovative cures and treatments to bring from bench to bedside.
The patients‘ enrollment starts at the Institute through an Institutional Review Board-approved clinical trial, then we obtain samples of both their normal and tumor tissue and analyze these samples using genomic sequencing techniques. In our state of the art clinical genomics lab, we also include the integration of Organoids for drug testing.
This sequencing strategy enables us to identify specific targets for treatment.
The results of our genomic analysis and patients’ medical history are reviewed by a multi-institutional Precision Medicine Tumor Board, which includes experts in medical oncology, pathology, computational biology, genetics, and ethics. The Tumor Board will collaboratively develop a treatment plan tailored to each patient, and EIPM will then share this plan with patients’ clinicians, who then discuss the results with the patient.
Our physicians follow the patients to see how they are responding to therapy and this information is captured in a clinical database that helps the EIPM team discover and develop therapeutic approaches to benefit many more patients with cancer and other diseases.[/vc_column_text]
Disease-targeting initiatives
Some of the most serious diseases can be traced in our genome. For these diseases, here in the Englander Institute for Precision Medicine (EIPM), we aim to deliver more effective treatments by identifying and characterizing genomic changes underlying genetic-based ailments.
In EIPM we are a translational research hub where we collaborate with clinical departments of WCM and NYP to provide a comprehensive interpretation of patient genomes and act as a permanent resource for our clinicians to make effective use of genomic data to optimize patient care.
To this end, we are channeling our efforts towards developing therapies where genomic data contribute significantly to the clinical result and offer hope for transforming health care.
These innovative research areas cover diseases such as:
Cancer Moonshot – Reaching for the stars